Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by gregoooon Nov 22, 2010 8:34pm

400 Views

Post# 17742524

RE: rig

looks like they are using a coiled tubing unit - from the press release :

DST 5, Lower Mirador, perforated 14,297 to 14,292 feet, five feet: coiled tubing was run to 6,000 feet and 500 standard cubic feet per minute of nitrogen was pumped to remove the fluid cushion, and achieved a drawdown of approximately 17 per cent. Fluid production rates averaged 2,225 barrels per day of 20.7-degree API oil with a trace of water during the test.

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale